Skyepharma says that it will begin developing a COPD therapy based on Pulmagen's ICS "re-sensitization" technology (SKP-2075) by the end of 2014 after acquiring the IP and global rights to the Theocort platform from Pulmagen. According to Skyepharma, it plans to spend about £14 million to develop SKP-2075 through Phase 2 and then will seek to out-license the product. … [Read more...] about Skyepharma acquires Pulmagen inhalation technology
News
Formex LLC hires John McCarty as Scientific Advisor
CDMO Formex, LLC has announced that former Azo Pharma VP of Formulation Development John McCarty has joined the company as Scientific Advisor. McCarty will also serve as a member of the company's Science Advisory Board. Formex cites McCarty's "broad expertise in the development of all major dosage forms" and "over 17" patents. Formex Chief Scientific Officer J. … [Read more...] about Formex LLC hires John McCarty as Scientific Advisor
Presspart to sell 3M dose counters
3M Drug Delivery Systems has announced that it has entered into a licensing agreement with Presspart for sales of the 3M Dose by Dose Counter and dose indicator. 3M DDS President and General Manager Cindy Kent said, “We are excited to partner with a company that possesses the expertise, resources and industry knowledge Presspart has to offer. They understand the … [Read more...] about Presspart to sell 3M dose counters
Cambridge Consultants to expand US drug delivery device development capability
Cambridge Consultants has announced plans to more than triple its US staff to 100+ over the next few years, with a focus on hiring for its medical technology business, especially drug delivery device development. The company has just moved its US headquarters to a new 20,000 sq ft facility Boston and is preparing to launch "an aggressive recruitment campaign" for … [Read more...] about Cambridge Consultants to expand US drug delivery device development capability
Insmed stock offering to support Arikayce development and commercialization
Insmed Incorporated is offering 8.9 million shares of common stock at $11.25 per share, with expected net proceeds of $94 million to go toward continued development of Arikayce liposomal amikacin for inhalation. The company recently announced that it plans to file an MAA for Arikayce for the treatment of refractory nontuberculous mycobacteria (NTM) lung infections and … [Read more...] about Insmed stock offering to support Arikayce development and commercialization
Sanofi partners with MannKind to commercialize Afrezza inhaled insulin
Sanofi will pay MannKind $150 million upfront and milestone payments of up to $775 million for an exclusive development and commercialization license for Afrezza insulin inhalation powder, the companies have announced. The companies will split profits and losses, with Sanofi's share being 65% and MannKind getting 35%. Afrezza, which was approved by the FDA in June … [Read more...] about Sanofi partners with MannKind to commercialize Afrezza inhaled insulin
Adasuve launched in Latin America
Alexza Pharmaceuticals partner Grupo Ferrer has launched its Adasuve loxapine inhalation powder in Guatemala, Alexza has announced. The approval in Guatemala is the first that Ferrer has obtained for Adasuve outside of Europe. Ferrer is responsible for regulatory and commercial activities related to Adasuve in the EU, Latin America and CIS countries. Ferrer Chief … [Read more...] about Adasuve launched in Latin America
Theravance appoints Michael W. Aguiar President and CEO
Theravance has announced that Michael W. Aguiar will replace Rick E Winningham as President and CEO effective August 15, 2014. Winningham will become CEO of Theravance Biopharma full time and will continue as Chairman of the Board of Directors of Theravance, Inc. Aguiar, who is currently Senior VP and Chief Financial Officer, joined Theravance in 2005 and led the … [Read more...] about Theravance appoints Michael W. Aguiar President and CEO
Aegis Therapeutics offers license for intranasal diabetes treatment
Aegis Therapeutics has announced the availability of "an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug." Aegis's intranasal product would be the only non-injectable formulation of exenatide, a GLP-1 analog that is currently marketed as Byetta and Bydureon by AstraZeneca. The intranasal … [Read more...] about Aegis Therapeutics offers license for intranasal diabetes treatment
Phase 1 study of Moerae Matrix’s inhaled MK2 inhibitor initiated
Moerae Matrix has announced the initiation of a Phase 1 clinical trial of MMI-0100, an inhaled MAPKAP Kinase 2 (MK2) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). In June 2012, the company announced an agreement with MicroDose Therapeutx (now part of Teva) to develop a dry powder inhalation delivery system for the drug. Moerae Matrix CEO … [Read more...] about Phase 1 study of Moerae Matrix’s inhaled MK2 inhibitor initiated